HomeAI · summaries
Storia in 3 fonti
Scribe Therapeutics surges 67% after $129M IPO as biotech market heats up
Scribe Therapeutics raised $128.7M in its upsized IPO and surged 67% on its Nasdaq debut, signaling renewed biotech investor appetite for CRISPR
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Scribe secures $129M in a rare gene editing IPO
The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most other biotech companies that have gone public in 2026.
- ·
endpoints.news
Gene editor Scribe Therapeutics starts second-half IPO spree with $129M listing
Scribe Therapeutics prices its Nasdaq IPO (SCTX), kicking off a wave of six biotechs expected to go public in the coming weeks.
